Publications by authors named "M-M Diallo"
Background: At the beginning of the 2018-2020 outbreak of Ebola virus disease (EVD) in eastern Democratic Republic of Congo (DRC), no vaccine had been licensed. However, cluster-randomized evidence from Guinea in 2015 had indicated that ring vaccination around new cases (targeting contacts and contacts-of-contacts) with the use of single-dose live-replicating rVSV-ZEBOV-GP vaccine reduced EVD rates starting 10 days after vaccination. Thus, ring vaccination was added to the standard control measures for that outbreak.
View Article and Find Full Text PDFArticle Synopsis
- RSV is a major cause of bronchiolitis, leading to 3 million hospitalizations each year, and nirsevimab is a monoclonal antibody aimed at preventing severe RSV cases in infants.
- A study compared infants hospitalized for RSV bronchiolitis with those visiting for unrelated reasons, assessing nirsevimab’s effectiveness in preventing hospitalizations in those under 12 months old.
- Findings showed nirsevimab reduced hospitalization rates for RSV-associated bronchiolitis by 83% and critical care needs by about 70%, indicating it is an effective treatment option for vulnerable infants.
Article Synopsis
- Researchers discovered that 4-octyl itaconate (4-OI) can enhance the effects of an oncolytic virus, VSVΔ51, in resistant cancer cells and models, leading to better treatment outcomes.
- The mechanism involves 4-OI suppressing antiviral immunity in cancer cells by modifying specific proteins, which suggests that combining metabolite-derived drugs with oncolytic viruses could significantly improve cancer treatment.
During the 2018-2020 Ebola virus disease (EVD) outbreak in North Kivu province in the Democratic Republic of Congo, EVD was diagnosed in a patient who had received the recombinant vesicular stomatitis virus-based vaccine expressing a ZEBOV glycoprotein (rVSV-ZEBOV) (Merck). His treatment included an Ebola virus (EBOV)-specific monoclonal antibody (mAb114), and he recovered within 14 days. However, 6 months later, he presented again with severe EVD-like illness and EBOV viremia, and he died.
View Article and Find Full Text PDFBackground: Survivors of childhood cancer are at risk of subsequent primary neoplasms (SPNs), but the risk of developing specific digestive SPNs beyond age 40 years remains uncertain. We investigated risks of specific digestive SPNs within the largest available cohort worldwide.
Methods: The PanCareSurFup cohort includes 69 460 five-year survivors of childhood cancer from 12 countries in Europe.
Background: Cardiac disease (CD) is one of the major side effects of childhood cancer therapy, but until now little has been known about the relationship between the heart radiation dose (HRD) received during childhood and the risk of CD.
Methods And Results: The cohort comprised 3162 5-year survivors of childhood cancer. Chemotherapy information was collected and HRD was estimated.
Context: Thyroid carcinoma is a frequent complication of childhood cancer radiotherapy. The dose response to thyroid radiation dose is now well established, but the potential modifier effect of other factors requires additional investigation.
Objective: This study aimed to investigate the role of potential modifiers of the dose response.
[Evaluation of the mean annual risk of tuberculosis infection in the town of Conakry].
Rev Mal Respir
October 1990
A study of tuberculous disease was carried out in children aged 5 to 13 years old who were first year pupils in primary schools in the town of Conakry (Republic of Guinae) with a view to determining the annual risk of tuberculous infection. In total 4,198 children distributed throughout 15 schools were tested after first looking for BCG vaccination scars. In the sample tested 1,444 children (34.
View Article and Find Full Text PDF